A prospective, non-randomized multi-center clinical investigation of the Venus P-Valve⢠for the treatment of pulmonary regurgitation with or without stenosis in patient with native outflow tracts.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Safety of Venus P-Valve⢠measured as probability of death/reoperation
Timeframe: month 12 follow-up
Safety of Venus P-Valve⢠measured as probability of Major Adverse Cardiac and Cerebro-vascular Event (MACCE)
Timeframe: month 1 follow-up
Performance of Venus P-Valve⢠measured as Success rate of valve placement and implantation
Timeframe: up to 30 days
Hemodynamic Performance of Venus P-Valve⢠measured as the mean transvalvular pressure (mmHg)
Timeframe: 1 month
Performance of Venus P-Valve⢠measured as change of pulmonary regurgitation (regurgitation classification by MRI)
Timeframe: baseline and month 6
Performance of Venus P-Valve⢠measured as change of pulmonary regurgitation (regurgitation classification by transthoracic echocardiogram)
Timeframe: baseline, day 1, month 1, 6, 12 and annually thereafter to 3 years post procedure
Performance of Venus P-Valve⢠measured as percentage of subjects with structural valve deterioration
Timeframe: month 6